^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    rovadicitinib (TQ05105)

    i
    Other names: TQ05105, Q05105, Q 05105, TQ 05105, Q-05105, TQ-05105
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    JAK inhibitor, ROCK inhibitor, ROCK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2d
    A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (clinicaltrials.gov)
    P1/2, N=45, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026
    Trial completion date
    |
    rovadicitinib (TQ05105)
    3ms
    TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients (clinicaltrials.gov)
    P1, N=9, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2024 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Aug 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Trial completion date • Trial termination • Trial primary completion date
    |
    Jakafi (ruxolitinib) • rovadicitinib (TQ05105)
    3ms
    To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects (clinicaltrials.gov)
    P1, N=32, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Completed | Trial primary completion date: Jul 2025 --> Mar 2025
    Trial completion • Trial primary completion date
    |
    rovadicitinib (TQ05105)
    10ms
    A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease (clinicaltrials.gov)
    P2, N=52, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=40 --> 52
    Enrollment change
    |
    rovadicitinib (TQ05105)
    1year
    TQ05105-III-01: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease (clinicaltrials.gov)
    P3, N=182, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • imatinib • methotrexate • rovadicitinib (TQ05105)
    1year
    Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease (clinicaltrials.gov)
    P3, N=182, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P3 trial
    |
    Rituxan (rituximab) • imatinib • methotrexate • rovadicitinib (TQ05105)
    1year
    To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    rovadicitinib (TQ05105)
    over1year
    A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (clinicaltrials.gov)
    P1/2, N=13, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    rovadicitinib (TQ05105)
    over1year
    A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease (clinicaltrials.gov)
    P2, N=40, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    rovadicitinib (TQ05105)
    over1year
    A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> May 2024
    Enrollment open • Trial initiation date
    |
    TQB3909 • rovadicitinib (TQ05105)
    over1year
    TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial
    |
    Jakafi (ruxolitinib) • rovadicitinib (TQ05105)
    over1year
    A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial
    |
    rovadicitinib (TQ05105)